PBI-4050 is a safe and effective therapy for patients with idiopathic pulmonary fibrosis (IPF), according to results of the now-completed Phase 2 clinical trial developed by ProMetic Life Sciences. The open-label, single-arm, Phase 2 study (NCT02538536) enrolled 40 IPF patients at six different sites in Canada to investigate the safety,…
Lung cells of patients with idiopathic pulmonary fibrosis (IPF) have higher than normal levels of two cytokines, small proteins crucial to the functioning of the immune system, according to a study. The researchers also discovered higher than normal levels of the cytokines interleukin 33 (IL-33) and thymic stromal lymphopoietin (TSLP)…
People with idiopathic pulmonary fibrosis (IPF) who have low levels of oxygen in the blood (hypoxemia) might be closer to having a new treatment option with the launch of a Phase 1 trial evaluating GBT440 in healthy volunteers, and two Phase 2 tests in select IPF patients. Global Blood…
Spanish patients with idiopathic pulmonary fibrosis (IPF) saw their hospital and follow-up care improve from 2004 to 2013, according to a new report. The study, “Retrospective observational study of trends in hospital admissions for idiopathic pulmonary fibrosis in Spain (2004–2013) using administrative data,” appeared in the journal BMJ Open. It…
A factor crucial to lung development also appears to promote fibrosis, the tissue-scarring in the lungs associated with idiopathic pulmonary fibrosis (IPF), according to a study. The factor, TAZ, locks lung fibroblasts — or cells that generate connective tissue — in a state that promotes fibrosis. TAZ stands for transcriptional co-activator with…
When idiopathic pulmonary fibrosis (IPF) patients experience sharp flares and sudden disease worsening, the bacterial make-up of their respiratory tract changes, a study has found. The research, “Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis,” compared patients whose condition had worsened because of an…
Increased deposits of iron in immune cells called macrophages were found to be independently correlated with pulmonary vascular resistance (PVR) in patients with idiopathic pulmonary fibrosis (IPF), according to a recent study. Findings of hemosiderin-laden (an iron-storage complex within cells) in macrophages in the lungs of IPF patients might also be…
Measuring disease-associated factors in sputum may be a less invasive way of tracking molecular changes in idiopathic pulmonary fibrosis (IPF) than bronchoalveolar washing, which involves sucking material from the lungs with a syringe, according to a study. Researchers found several factors in IPF patients at higher levels than in healthy people…
A secreted factor from bone marrow stem cells (BMSC-cm) improves the function of alveolar epithelial cells in repair and regeneration. These results support a potential therapeutic role for BMSC-cm released factors in idiopathic pulmonary fibrosis (IPF) and other lung diseases. The study “Hepatocyte growth factor secreted by bone marrow…
Patients with idiopathic pulmonary fibrosis (IPF) who rapidly gain weight may have a poorer prognosis than those with lesser weight gains, particularly if they never smoked. Researchers also linked to poorer survival a notable decline in lung function with one year, and a jump in the number of hospitalizations for airway problems. The study,…
Get regular updates to your inbox.
